SEARCH

SEARCH BY CITATION

References

  • 1
    Gupta AK, Ryder JE, Johnson AM. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. Br J Dermatol2004; 150: 53744.
  • 2
    Faergemann J, Anderson C, Hersle K et al. Double blind, parallel group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. J Am Acad Dermatol1995; 32: 7503.
  • 3
    Heikkilä H, Stubb S, Reitamo S. A study of 72 patients with contact allergy to tioconazole. Br J Dermatol1996; 134: 67880.
  • 4
    Matricciani L, Talbot K, Jones S. Safety and efficacy of tinea pedis and onychomycosis treatment in people with diabetes: a systematic review. J Foot Ankle Res2011; 4: 26.
  • 5
    Elewski B, Pollak R, Ashton S, Rich P, Schlessinger J, Tavakkol A. A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Br J Dermatol2012; 166: 38998.
  • 6
    Brown SJ. Efficacy of fluconazole for treatment of onychomycosis. Ann Pharmacother2009; 43: 168491.
  • 7
    Trivedi NA, Shah PC. A meta-analysis comparing efficacy of continuous terbinafine with intermittent itraconazole for toenail onychomycosis. Indian J Dermatol2010; 55: 1989.
  • 8
    Yin Z, Xu J, Luo D. A meta-analysis comparing long-term recurrences of toenail onychomycosis after successful treatment with terbinafine versus itraconazole. J Dermatolog Treat2011; [Epub ahead of print].
  • 9
    Piraccini BM, Sisti A, Tosti A. Long-term follow-up of toenail onychomycosis caused by dermatophytes after successful treatment with systemic antifungal agents. J Am Acad Dermatol2010; 62: 4114.
  • 10
    de Berger D. Fungal nail disease. N Engl J Med2009; 360: 210816.
  • 11
    Gupta AK, Uro M, Cooper EA. Onychomycosis therapy: past, present, future. J Drugs Dermatol2010; 9: 110913.
  • 12
    Baran R, Hay RJ, Garduno JI. Review of antifungal therapy, part II: treatment rationale, including specific patient populations. J Dermatolog Treat2008; 19: 16875.
  • 13
    Gupta AK, Cooper EA. Update in antifungal therapy of dermatophytosis. Mycopathologia2008; 166: 35367.
  • 14
    Sigurgeirsson B, Olafsson JH, Steinsson JT, Kerrouche N, Sidou F. Efficacy of amorfine nail lacquer for the prophylaxis of onychomycosis over 3 years. J Eur Acad Dermatol Venereol2010; 24: 9105.
  • 15
    Watanabe S, Harada T, Hiruma M et al. Epidemiological survey of foot diseases in Japan: results of 30,000 foot checks by dermatologists. J Dermatol2010; 37: 397406.
  • 16
    Gupta AK, Joseph WS. Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States. J Am Podiatr Med Assoc2000; 90: 495501.
  • 17
    Finch JJ, Warshaw EM. Fungal nail infections: diagnosis and management. Prescrire Int2009; 18: 2630.
  • 18
    Gupta AK, Drummond-Main C, Cooper EA, Brintnell W, Piraccini BM, Tosti A. Systematic review of nondermatophyte mould onychomycosis: diagnosis, clinical types, epidemiology, and treatment. J Am Acad Dermatol2012; 66: 494502.
  • 19
    Ko JY, Lee HE, Jae H, Oh DH, Kim JS, Yu HJ. Cure rate, duration required for complete cure and recurrence rate of onychomycosis according to clinical factors in Korean patients. Mycoses2011; 54: 3848.
  • 20
    Crawford F, Hollis S. Topical treatments for fungal infections of the skin and nails of the foot. Cochrane Database Syst Rev2007; 3: CD001434.
  • 21
    Elewski BE, Ghannoum MA, Mayser P et al. Efficacy, safety and tolerability of topical terbinafine nail solution in patients with mild-to-moderate toenail onychomycosis: results from three randomized studies using double-blind vehicle-controlled and open-label active-controlled designs. J Eur Acad Dermatol Venerol2011 doi:10.1111/j.1468-3088.2011.04373.x. [Epub ahead of print].
  • 22
    Nasir A, Goldstein B, van Gleeff M, Swick L. Clinical evaluation of safety and efficacy of a new topical treatment for onychomycosis. J Drugs Dermatol2011; 10: 118691.
  • 23
    Menéndez S, Falcón L, Maqueira Y. Therapeutic efficacy of topical Oleozon® in patients suffering from onychomycosis. Mycoses2011; 54: 2727.
  • 24
    Derby R, Rohal P, Jackson C, Beutler A, Olsen C. Novel treatment of onychomycosis using over-the-counter mentholated ointment: a clinical case series. J Am Board Fam Med2011; 24: 6974.
  • 25
    Romero-Cerecero O, Zamilpa A, Jiménez-Ferrer JE, Rojas-Bribiesca G, Román-Ramos R, Tortoriello J. Double-blind clinical trial for evaluation the effectiveness and tolerability of Argentina pichinchensis extract on patients with mild to moderate onychomycosis. A comparative study with ciclopirox. Planta Med2008; 74: 14305.
  • 26
    Bassiri-Jahromi S, Ehsani AH, Mirshams-Shahshahani M, Jamshidi B. A comparative evaluation of combination therapy of fluconazole 1% and urea 40% compared with fluconazole 1% alone in a nail lacquer for treatment of onychomycosis: therapeutic trial. J Dermatolog Treat2011; [Epub ahead of print].
  • 27
    Shemer A, Nathansohn N, Trau H, Amichai B, Grunwald MH. Ciclopirox nail lacquer for the treatment of onychomycosis: an open non-comparative study. J Dermatol2010; 37: 1379.
  • 28
    Sipponen A, Laitinen K. Antimicrobial properties of natural coniferous rosin in the European Pharmacopoeia challenge test. APMIS2011; 119: 7204.
  • 29
    Rautio M, Sipponen A, Peltola R et al. Antibacterial effects of home-made resin salve from Norway spruce (Picea abies). APMIS2007; 115: 335340.
  • 30
    Rautio M, Sipponen A, Lohi J, Lounatmaa K, Koukila-Kähkölä P, Laitinen K. In vitro fungistatic effects of natural coniferous rosin from Norway spruce (Picea abies). Eur J Clin Microbiol Infect Dis2012; 31: 17839.
  • 31
    Sipponen A, Peltola R, Jokinen JJ et al. Effects of Norway spruce (Picea abies) resin on cell wall and cell membrane of Staphylococcus aureus. Ultrastruct Pathol2009; 33: 12835.
  • 32
    Sipponen A, Jokinen JJ, Sipponen P, Papp A, Sarna S, Lohi J. Beneficial effect of resin salve in treatment of severe pressure ulcers: a prospective, randomized and controlled multicentre trial. Br J Dermatol2008; 158: 105562.
  • 33
    Sipponen A, Kuokkanen O, Tiihonen R, Kauppinen H, Jokinen JJ. Natural coniferous resin salve used to treat complicated surgical wounds: pilot clinical trial on healing and costs. Int J Dermatol2012; 51: 72632.
  • 34
    Baran R, Hay RJ, Tosti A, Haneke E. A new classification of onychomycosis. Br J Dermatol1998; 139: 56771.
  • 35
    von Elm E, Altman DG, Egger M et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol2008; 61: 3449.
  • 36
    Malay DS, Yi S, Borowsky P, Downey MS, Mlodzienski AJ. Efficacy of debridement alone versus debridement combined with topical antifungal nail lacquer for the treatment of pedal onychomycosis: a randomized, controlled trial. J Foot Ankle Surg2009; 48: 294308.
  • 37
    Heikkilä H. Isolation of fungi from onychomycosis-suspected nails by two methods: clipping and drilling. Mycoses1996; 39: 47982.
  • 38
    Daniel CR 3rd, Daniel MP, Daniel CM, Sullivan S, Ellis G. Chronic paronychia and onycholysis: a thirteen-year experience. Cutis1996; 58: 397401.
  • 39
    Ghannoum MA, Hajjeh RA, Scher R et al. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol2000; 43: 6418.
  • 40
    Suhonen R. Onychomycosis. Duodecim1997; 113: 4336.
  • 41
    Baudraz-Rosselet F, Ruffieux C, Lurati M, Bontems O, Monold M. Onychomycosis insensitive to systemic terbinafine and azole treatments reveals non-dermatophyte moulds as infectious agents. Dermatology2010; 220: 1648.
  • 42
    Shemer A, Davidovici B, Grunwald MH, Trau H, Amichai B. New criteria for the laboratory diagnosis of nondermatophyte moulds in onychomycosis. Br J Dermatol2009; 160: 379.
  • 43
    Bontems O, Hauser PM, Monod M. Evaluation of a polymerase chain reaction-restriction fragment length polymorphisms assay for dermatophyte and nondermatophyte identification in onychomycosis. Br J Dermatol2009; 161: 7916.
  • 44
    Amichai B, Davidovici B, Trau H, Lyakhovitsky A, Grunwald MH, Shemer A. A rationale for systemic treatment in onychomycosis with negative results on fungal examination. Clin Exp Dermatol2011; 36: 7247.
  • 45
    Robert R, Pihet M. Conventional methods for the diagnosis of dermatophytosis. Mycopathologia2008; 166: 295306.
  • 46
    Farwa U, Abbasi SA, Mirza IA et al. Non-dermatophyte moulds as pathogens of onychomycosis. J Coll Physicians Surg Pak2011; 21: 597600.
  • 47
    Sigurgeirsson B. Prognostic factors for cure following treatment of onychomycosis. J Eur Acad Dermatol Venerol2010; 24: 67984.
  • 48
    Shemer A, Trau H, Davidovici B, Amichai B, Grunwald MH. Onychomycosis: rationalization of topical treatment. Isr Med Assoc J2008; 10: 4156.